Training is the stimulus. It is not the adaptation. That happens later — in the hours we treat as leftover time, and describe with words that all mean absence: rest day, off day, recovery day.

This week Pete brings Srdjan a piece of research that has nothing to do with the gym and everything to do with it. In 2007, Sabine Sonnentag and Charlotte Fritz published the Recovery Experience Questionnaire, built on a puzzle they kept running into: hours off didn’t predict who came back restored. Two people take the same weekend. One returns ready. One returns wrecked. Their answer was that recovery isn’t one thing — it’s four, and they don’t substitute for each other. Psychological detachment. Relaxation. Mastery. Control. If you spend all day being told what to do, lying on the couch won’t fix it; you need a rest that hands you back the controls.

Srdjan takes that framework into the gym and it holds up uncomfortably well. He walks through what’s actually happening in your body after a hard session — glycogen, protein synthesis, the twenty-four to forty-eight hour repair window — and makes the case that soreness is a lousy measurement of recovery, because different systems come back online at different speeds. Muscles, energy stores, connective tissue, nervous system. None of them are on the same clock.

Recovery isn’t separate from training. It is the training. Let’s build.

Links & Notes

• The Recovery Experience Questionnaire (Sonnentag & Fritz, 2007) — the four-factor model of detachment, relaxation, mastery, and control. Free full text, and the paper that kicked off this whole episode. Also on PubMed.
• Insufficient Sleep Undermines Dietary Efforts to Reduce Adiposity (Nedeltcheva et al., Annals of Internal Medicine, 2010) — the metabolic ward study, 8.5 versus 5.5 hours of sleep opportunity.
• Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy Men (Leproult & Van Cauter, JAMA, 2011).
• The Effects of Sleep Extension on the Athletic Performance of Collegiate Basketball Players (Mah et al., Sleep, 2011) — every player improved on every measure.
• Gaining More From Doing Less? (PeerJ, 2024) — the thirty-nine-lifter deload study. Free full text.
• Work with Srdjan and the team at ELEV8 Fitness in Portland, Oregon.
• Submit your questions to the show!

Cortisol gets described online as the thing standing between you and the body you want. It's actually the hormone that gets you out of bed. It runs on a daily curve, highest in the morning and lowest at night, and it regulates blood sugar, blood pressure, inflammation, and how much energy the body makes available when something demands it. Exercise raises it. That's the point of exercise.

A hard session raises cortisol for a few hours, then it settles. Chronic stress never allows the settling. The body doesn't keep separate accounts for work, caregiving, money, bad sleep, and training. It adds them up, and when the total outruns the capacity to recover, strength stalls and motivation goes, and the natural conclusion is that the program isn't working.

An acute training spike is a different condition than chronically elevated cortisol, and treating them as the same thing is how people end up buying a supplement to solve a sleep problem. "Cortisol belly" turns out to be a product category. Five hours a night turns out to have a price.

Plus: the case for walking into the gym anyway on the worst days.

Links & Notes

On cortisol's normal daily rhythm

• Cortisol Awakening Response: Regulation and Functional Significance — Endocrine Reviews
• The circadian system modulates the cortisol awakening response in humans — Frontiers in Neuroscience

On exercise, cortisol, and stress regulation

• Effects of a 12-week endurance training program on the physiological response to psychosocial stress in men: a randomized controlled trial — Journal of Behavioral Medicine
• The effects of exercise intensity on the cortisol response to a subsequent acute psychosocial stressor

On "cortisol belly"

• The 'cortisol belly' myth: when diet culture is rebranded as wellness — The Conversation
• 9 Myths About the 'Stress Hormone' Cortisol — TIME
• Routine Screening for Cushing's Syndrome Is Not Required in Patients Presenting with Obesity

On sleep

• Sleep loss lowers testosterone in healthy young men — UChicago Medicine (Leproult & Van Cauter, JAMA 2011 — the 10–15% finding)
• Sleep loss boosts hunger and high-calorie food choices — University of Chicago
• Impact of Five Nights of Sleep Restriction on Glucose Metabolism, Leptin and Testosterone in Young Adult Men — PLOS One

On energy availability and reproductive hormones

• Hypogonadism in Exercising Males: Dysfunction or Adaptive-Regulatory Adjustment?

Show links

• ELEV8 Fitness
• Submit your questions to the show!

A calorie deficit takes energy away. Building muscle demands it. Whether you can do both at once depends almost entirely on where you're starting from, and the answer for a beginner is not the answer for someone ten years in.

Exercise order comes next. The case for doing compound lifts first has nothing to do with those lifts being better. It's about energy: what a squat asks of you versus what a leg extension asks, and what happens to your form once the tank is empty. There are limits to that rule, and they're worth knowing before you treat it as gospel.

Then the timeline questions. One listener has a baby on the way and a month with no gym in front of him, and wants to know when "you don't lose it that fast" stops being true. Another is 67. His doctor just told him muscle is the organ of longevity and to start lifting. His adult kids are terrified.

Then the peptide mail. What an FDA advisory vote actually does, and what it doesn't. Why a yes vote is not an approval. Who pays for trials on a molecule nobody can patent, and what happens if the answer is nobody. Plus a listener six weeks into treating his own elbow, asking when "we need more human trials" stops being caution and starts being a gate.

Corrections & Context

We check the big factual claims after every episode. Here's what needs fixing, what needs more context, and what held up. Everything links to a source so you can check us.

What we got wrong

1. You can't currently get these peptides from a compounding pharmacy. On air we described the FDA committee's vote as clearing the way for a doctor to write a prescription and a compounding pharmacy to fill it. That isn't where things stand. The Pharmacy Compounding Advisory Committee met July 23–24, 2026 and voted, but an advisory committee vote is not an agency action. Nothing has legally changed. Before any of these substances can be compounded, the FDA has to accept the recommendation and add it to the 503A Bulks List through formal notice-and-comment rulemaking, and that process hasn't started. As of this writing, none of the seven peptides reviewed in July can legally be compounded. → FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do — Mintz (July 29, 2026) → What the Peptide Vote Actually Changes at My Counter (Hint: Not Much, Yet) — Pharmacy Times

One thing to separate out: plenty of peptides remain legally compoundable and always have. The seven under review are the exception.

2. The FDA did not lose in court. We said the agency "lost in court" and that's why the peptides came back. No such loss happened. The path back ran through the executive branch: the FDA removed twelve peptides from Category 2 in April 2026 after their nominations were withdrawn, then sent them to the advisory committee. Where compounding has actually been fought in court lately — the Outsourcing Facilities Association suits over GLP-1 shortage delisting — the FDA won. Judges denied the compounders' injunctions in both the semaglutide and the tirzepatide cases. → FDA clarifies policies for compounders — U.S. Food and Drug Administration → Court Backs FDA in Tirzepatide Compounding Case — McDermott

3. "Peptides are not drugs" is backwards. "Peptide" describes a chemical: a short chain of amino acids. "Drug" describes a legal category. Something can be both, and most peptide medicines are. Ozempic and Wegovy are FDA-approved drugs whose active ingredient is a peptide. BPC-157 is also a drug under federal law, just an unapproved one, which is why selling it for human use is illegal. Your body making peptides doesn't change that, any more than your body making cortisol makes prednisone a supplement. This is our own basil-and-nightshade point from the peptides episode, and we dropped it. → Wegovy (semaglutide) prescribing information — FDA → Understanding the Legal Risks of BPC-157 and Other Unapproved Peptides — Holt Law

4. "There are no human trials, and there never will be any" is too strong on both halves. Human studies exist. They're small, old, and mostly unpublished in full. Under the development name PL-14736, BPC-157 went through a safety and pharmacokinetics study in healthy volunteers (Gut, 2003) and a randomized, double-blind, placebo-controlled Phase II study in ulcerative colitis (Gastroenterology, 2005). A Phase I safety trial in 42 volunteers was registered in 2015 (NCT02637284) and cancelled without published results. The most recent human data is a 2025 intravenous safety pilot in two people. Fewer than thirty published human subjects, total. That's a bad number, but it isn't zero, and "no trials" and "almost no data" lead to different conversations.

The "never will be" half is fair as far as it goes. A molecule without strong patent protection has little commercial money behind it. But academic and government-funded trials happen all the time. And there's an irony from the committee itself: some members argued that allowing compounding would open the door to more study, while the counterargument is that selling it commercially removes any reason to ever run the trial. → Is BPC-157 safe for use in humans? — InpharmD evidence summary, with primary citations → Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — PubMed

5. The vote was six of seven, not two — and our earlier reporting needs updating too. We've been describing the July meeting as a narrow win for BPC-157 and KPV with the others still pending. The final tally: the committee recommended adding BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax to the 503A list, and voted againstemideltide (DSIP). Two things matter more than the count. The FDA's own scientific reviewers recommended against all seven. And each peptide was judged against one specific medical use — BPC-157 was assessed for ulcerative colitis, not tendons or elbows or recovery. The uses driving all the demand were never on the ballot. → FDA Expert Panel Backs Compounding of Six Peptides — Medscape → FDA briefing documents and meeting materials, July 23–24, 2026 PCAC

6. There is no 300-pound threshold for GLP-1 medications. We talked about eligibility in pounds. The FDA label uses BMI: 30 or greater, or 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Someone hoping to lose twenty-five pounds may well qualify. Someone who weighs three hundred p...

Part one covered the fight. This one covers the food.

Four peptides get walked through one at a time. BPC-157 and TB-500 are the recovery pair — the ones most often discussed together, and the ones most often sold together. The claim is that one improves the conditions for healing by supporting blood flow and collagen production, while the other helps repair cells reach the damage faster. Neither is a painkiller. Neither creates healing. The pitch is that they make the body better at a job it already knows how to do.

Getting there means a detour through inflammation, which turns out to be the wrong villain. Inflammation is the opening move in every repair your body has ever completed. The problem isn't that it happens — it's when it won't leave. Then the conversation shifts to the other end of the shelf: the growth hormone stack, what a secretagogue actually does, and why IGF-1 has a longer-acting cousin that bodybuilders care about.

Running underneath all of it: the reason a peptide can't do anything for someone who sleeps five hours and eats eighty grams of protein a day.

Nothing in this episode is medical advice. Recorded early August 2026, while the FDA's final decision was still pending.

The show

• ELEV8 Fitness: https://elev8fitnesspdx.com
• Submit your questions!

A peptide is a short chain of amino acids. That's the entire definition. Insulin is a peptide. So is the drug in Ozempic. So are BPC-157 and TB-500 — compounds athletes have used for injury recovery for years, and which the FDA moved to a restricted list in September 2023, citing limited human safety data.

In late July, an FDA advisory committee spent two days voting on whether pharmacies should be allowed to make seven of them again. Six passed. Every vote was close. The agency's own scientists had recommended against all seven.

This episode covers what a peptide actually is, and why the word alone tells you nothing about whether something is safe. Why compounding pharmacies sit at the center of a fight involving big pharma, a federal agency, and a health secretary who has called himself a fan. What the research on BPC-157 actually consists of — and why "over a hundred studies" is a more complicated number than it sounds. And the distinction that most of the coverage got wrong: legal to compound is not the same as FDA-approved, and nothing changed at the pharmacy counter the day after that vote.

Also in here: what happens to a supply chain when the legal version disappears, the gas-station-sushi test for anything you're considering injecting, and why one strength coach is booking a conversation with his physician about his own shoulder.

Nothing in this episode is medical advice. The recommendation, start to finish, is the same one: talk to your doctor.

The news, as of this episode

• FDA advisory panel narrowly backs six of seven peptides — Associated Press via PBS NewsHour: https://www.pbs.org/newshour/health/watch-live-day-2-of-fda-advisory-panel-meeting-to-consider-use-of-peptides
• Panel backs epitalon and semax, rejects emideltide — STAT, July 24, 2026: https://www.statnews.com/2026/07/24/fda-peptide-compounding-panel-backs-epitalon-rejects-emideltide/
• FDA staff and peptide advocates clash at advisory panel — STAT, July 23, 2026: https://www.statnews.com/2026/07/23/fda-advisory-panel-peptide-safety-compounding-pharmacies/
• What the peptides are and what happens next — CNN, July 31, 2026: https://edition.cnn.com/2026/07/31/health/what-are-peptides-fda-next-steps-wellness
• FDA panel supports broadening access — NPR, July 23, 2026: https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions
• Vote-by-vote breakdown — American Journal of Managed Care: https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
• Committee backs two more, rejects one — Regulatory Affairs Professionals Society: https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html

What the vote does and doesn't do

• A pharmacist on what the reclassification actually means — Pharmacy Times: https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means
• Legal analysis of the committee's votes — Mintz: https://www.mintz.com/insights-center/viewpoints/2146/2026-07-29-fdas-advisory-committee-votes-peptides-what-it-does-and
• FDA's removal of twelve peptides from Category 2, and what it doesn't mean — Orrick: https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings

On the conflict-of-interest question

• FDA advisers back looser rules for six peptides — Bloomberg Law: https://news.bloomberglaw.com/health-law-and-business/fda-review-committee-rejects-first-peptide-in-second-day-hearing

Primary source

• FDA: July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

The show

• ELEV8 Fitness: https://elev8fitnesspdx.com
• Submit your questions!

A two-week break feels like a setback and mostly isn't. What changes first is muscle fullness, not muscle tissue — glycogen and the water bound to it, drained by less training and different eating. The muscle deflates. It doesn't shrink. In trained lifters, strength has held steady across exactly this kind of layoff.

The harder problem is the gym itself. Walk into an unfamiliar facility with a program written for equipment that isn't there, and you'll either wander or quietly overload one muscle group while ignoring its opposite. There's a portable structure that solves both, and it doubles as a survival tactic on a crowded floor — where the rules nobody posts turn out to matter most: how to ask to work in, what a towel on a bench actually reserves, and whether you're allowed to interrupt a stranger to ask what that exercise was.

Coming back is the part people rush. The strength is still there, but the runway matters. And the thing most people actually lose on a trip isn't muscle — it's the routine, which is the harder one to rebuild.

Links & Notes

Train with the crew at ELEV8 Fitness — personal training, group classes, and open gym memberships are all a short drive away.

The gym Pete trained at on the road: Chautauqua Health & Fitness Center at Turner Community Center, a year-round facility on the grounds of Chautauqua Institution.

At a routine physical, a doctor charts blood pressure, weight, cholesterol, and triglycerides — a page of numbers meant to forecast the years ahead. None of them measure how strong you are. That's a strange omission, because muscle strength is one of the most reliable predictors of both lifespan and healthspan that researchers have found — in some studies, a better predictor than the blood-pressure reading sitting right next to it on the chart. This episode of Build for Health, with host Pete Wright and ELEV8 strength coach Srdjan Injac, examines the gap between what the exam room measures and what actually keeps a body running — and why that gap exists in the first place.

The trail starts in medical training itself. Across four years of U.S. medical school, students receive on average roughly nineteen hours of nutrition education — under one percent of total instruction — and most of that is biochemistry, not how to counsel a patient on what to eat for breakfast. The result isn't ignorant doctors; it's a system built to diagnose and treat disease rather than prevent it, and one that gives a clinician about eight minutes per visit to do it. From there the episode turns to what the research actually rewards: grip strength, leg strength, walking speed, and total muscle mass — each of which tracks with how long and how independently people live. Low muscle mass even has a clinical name, sarcopenia, and a real cost, from falls and fractures to the loss of being able to stand up unassisted. The throughline is that strength isn't cosmetic. It's infrastructure.

Underneath the specifics is a harder question about who owns prevention. When a visit is built around treating the number — a statin for cholesterol, a pill for blood pressure, another for blood sugar — the lifestyle changes that move the underlying condition can go unmentioned. Type 2 diabetes is the sharpest example: in clinical trials, substantial weight loss has put nearly half of shorter-duration cases into remission. The takeaway isn't that medicine is the enemy, and it certainly isn't that anyone should stop a prescription on their own. It's that absence of advice is not absence of importance — and that the strongest move a patient can make is to walk into the exam room asking not just how to fix a number, but how to keep it from coming back.

KEY TAKEAWAYS

• Strength is an unmeasured vital sign. A standard physical records a dozen numbers that predict your health — but not how strong you are, even though strength rivals or beats several of them as a predictor.
• Grip strength is a whole-body signal. It correlates with all-cause mortality, cardiovascular disease, and future disability — in large prospective research, more strongly than systolic blood pressure. (The point isn't to train your hands; grip is a proxy for total-body strength and resilience.)
• Walking speed predicts survival. Especially after age 65, usual walking pace integrates strength, balance, cardiovascular fitness, and nervous-system function into one accessible measure of vitality.
• Leg strength buys independence. The legs hold the largest muscles in the body; maintaining them lowers the risk of falls, fractures, and the loss of everyday autonomy — including the ability to get up off the floor, or off the toilet, without help.
• Low muscle mass has a name and a cost. Sarcopenia — age-related loss of muscle — is linked to higher disease and disability risk. You can carry less mass and still be strong, which is why strength, not size, is the goal.
• Med school barely covers nutrition. U.S. medical students average ~19 hours of nutrition across four years, under 1% of instruction — and most of it is biochemistry, not practical dietary counseling. The gap is structural, not personal.
• Lifestyle can move the underlying condition, not just the number. Resistance training, better nutrition, and weight loss can improve blood pressure, cholesterol, and blood sugar at the source. Type 2 diabetes remission is well-documented in shorter-duration cases following significant weight loss.
• Ask prevention questions, not just prescription questions. "How do I keep this from coming back?" is a different conversation than "What do I take for this?"

Safety note: Nothing here is medical advice, and no one should start, stop, or change a medication on their own. Decisions about prescriptions — including any wind-down — belong with your own clinician.

GLOSSARY

• Sarcopenia — Age-related loss of skeletal muscle mass and strength; associated with higher risk of falls, disability, and disease.
• Grip strength — Force generated by the hand, typically measured with a hand dynamometer. Used as a low-cost proxy for total-body strength and a research-validated predictor of mortality and disease risk.
• Gait speed (walking speed) — Usual walking pace, measured over a short distance. A simple, strong indicator of healthy aging and survival because it draws on multiple body systems at once.
• Sarcopenia vs. weakness — You can have less muscle mass but still be strong; the episode stresses that strength and function matter more than size alone.
• Type 2 diabetes remission — Return of blood sugar to a non-diabetic range without medication, sustained through lifestyle change. Remission is documented (especially in shorter-duration disease) but is not the same as a permanent cure; it depends on maintaining the habits.
• Statin — A class of drugs that lowers cholesterol; cited as an example of treating the number rather than the cause.
• Insulin resistance — Reduced response of cells to insulin, a key driver of type 2 diabetes; improved by activity, muscle, and fat loss.
• Naturopath / naturopathic medicine — A practitioner approach that, as described in the episode, emphasized longer visits, lifestyle, and prevention. (Scope of practice and licensing vary by state.)

LINKS & NOTES

• Sawbones: A Marital Tour of Misguided Medicine — Dr. Sydnee McElroy and Justin McElroy's medical-history podcast (Maximum Fun): https://maximumfun.org/podcasts/sawbones/
• ELEV8 Fitness: https://elev8fitnesspdx.com

The evidence behind this episode

• Nutrition in med school: "The State of Nutrition Education at US Medical Schools," Journal of Biomedical Education, 2015 — https://onlinelibrary.wiley.com/doi/10.1155/2015/357627
• Grip strength vs. blood pressure as a mortality predictor: Leong et al., PURE study, The Lancet, 2015 — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62000-6/abstract
• Walking speed and survival: Studenski et al., "Gait Speed and Survival in Older Adults," JAMA, 2011 — https://doi.org/10.1001/jama.2010.1923
• Type 2 diabetes remission via weight loss: Lean et al., DiRECT trial, The Lancet, 2018 — https://pubmed.ncbi.nlm.nih.gov/29221645/

ELEV8 trainer Devon Castro joins hosts Pete Wright and Srdjan Injac to take on a familiar fear: that a vacation will erase a year of training. It doesn't hold up. Muscle is durable: meaningful loss takes weeks of true inactivity, not a long weekend, and the "deflated" look people notice after a few days off is water and glycogen shifting — not muscle disappearing. Cardio fades faster than strength, which is why a swim, a hike, or a morning run protects the fitness that actually slips first.

Maintaining doesn't require a real gym, either. A handful of big compound movements or a short bodyweight circuit — roughly twenty minutes, a couple of times a week — is enough to hold muscle, because the largest muscle groups recruit the smaller ones for free. Then there's everything that doesn't look like exercise: walking a new city, stairs, carrying bags. That non-exercise movement adds up to real energy expenditure, and it's often higher on vacation than at a desk. On food, the episode pushes back on a familiar rule — breakfast isn't a metabolic switch that makes or breaks weight, but a protein-forward first meal does a real job on a chaotic travel day: it adds structure and keeps you from arriving at dinner ravenous. Skipping it works fine for some people; what matters is the whole day, not the clock. And sleep turns out to be the quiet anchor under all of it — short sleep nudges you toward more food and worse decisions the next day.

Vacation isn't a training phase, and treating it like one is the actual mistake. The goal isn't progress — it's coming home without losing ground and without white-knuckling the whole trip. Move a little, eat with a couple of anchors, protect your sleep, and enjoy the thing you traveled for.

KEY TAKEAWAYS

• A week or two off costs you almost nothing. Real muscle loss takes weeks of inactivity; "mature" muscle built over years is even more durable.
• Feeling "flat" isn't losing muscle. It's water and glycogen shifting, and it bounces back fast once you're eating and moving normally.
• Cardio fades faster than strength. If you keep one thing up, make it a swim, hike, or run — that's what slips first.
• You don't need equipment or an hour. Three compound movements, or a bodyweight HIIT circuit, ~20 minutes, twice a week, maintains muscle.
• Train the big stuff. Large compound movements recruit the smaller muscles automatically — skip the isolation work on the road.
• NEAT is real and underrated. All the incidental walking, stairs, and sightseeing is genuine energy expenditure, often higher than your normal desk-bound day.
• Breakfast isn't magic for weight. But a protein-forward first meal adds structure and prevents the over-hungry dinner blowout. Skipping is fine for many people; total daily intake is what matters. (Exception: people with blood-sugar regulation issues should eat earlier — confirm framing, see production notes.)
• Sleep is the keeper. Poor sleep drives overeating and worse choices — protecting it beats forcing a workout.
• Moderation beats restriction. The enemy isn't the gelato; it's the all-or-nothing rebound that turns one treat into a five-day write-off.

Spend ten minutes on the wellness internet and you'll learn that women's health runs on one vengeful hormone, that carbs are a betrayal, and that the fix is a protocol synced to your cycle. The kernel of truth — most fitness research was done on men — keeps getting buried under products, calendars, and miracle drugs. This episode digs for the science underneath.

What actually changes when you train a woman instead of a man? Less than you'd think. From there: the real cost of GLP-1 drugs, what fasting and keto quietly do to hormones and energy, whether cycle-syncing is science or a $40 grift, and why cortisol isn't the villain your feed makes it out to be.

The throughline is the least marketable advice in fitness: balance beats extremes, and the scale is the wrong thing to track. Every shortcut here sells speed at the expense of the one thing that compounds over a lifetime — the muscle and bone you build the slow way.

Key Takeaways

• Programming for women and men is more alike than different. Same core exercises; the real variables are intensity and recovery, adjusted to where someone is in their cycle and how they feel day to day.
• "Bulky" is largely a myth. Building significant size is genuinely hard and isn't a default risk of lifting heavy.
• GLP-1 medications carry an off-label cost. Roughly a quarter of the weight lost can be muscle, and falling estrogen accelerates bone loss — a setup for osteopenia and, later, osteoporosis.
• The drugs are legitimately useful for real medical need, but become a problem when used as a permanent shortcut with no nutrition education and no training to protect muscle.
• Fasting and keto trade fast scale drops for thyroid suppression, disrupted estrogen, irregular or missing periods, and lower energy — and the effects hit lean, active women hardest.
• Carbs aren't the enemy. A floor of about 150g per day supports estrogen and thyroid function; too little for too long reads to the body as a famine signal.
• Cycle phases are real, but cycle-syncing products oversell them. Strength tends to peak in the follicular-to-ovulatory window; the luteal phase brings fatigue, cravings, bloating, and water retention. The answer is personalization and adapting effort — not quitting the gym.
• Cortisol is essential, not evil. It regulates energy, blood sugar, and the sleep-wake cycle. Chronic elevation is the issue, and even then it works through behavior (cravings, poor sleep, low recovery) rather than directly causing fat gain.
• The scale lies daily. Two-to-five-pound swings in 24 hours are normal and almost never fat. Track body composition and performance instead.
• The shortcut is the trap. Medications, extreme diets, and trend protocols sell speed; muscle and bone are built slowly and pay off for the rest of your life.

Liked what you heard? Srdjan, Brooke, and Kaila are all coaches at ELEV8 Fitness — and you can train with them in real life, not just in your earbuds. No shortcuts, no $40 cycle calendars. Just real programming built for your body and your life. Start at elev8fitnesspdx.com.

Most people picture the skeleton as a rigid frame — inert scaffolding that holds everything else up. It isn't. Bone is living tissue, constantly broken down and rebuilt, and it responds to stress exactly the way muscle does: load it, and it grows stronger and denser. That one fact changes the whole question. Bone health isn't something you're stuck with — it's something you build, and the same training that builds muscle is reinforcing the skeleton underneath it.

The rebuilding runs on a process called remodeling: specialized cells called osteoclasts clear away old, damaged bone while osteoblasts lay down new tissue. Peak bone mass arrives in the late twenties to early thirties, and from there it's a slow decline — faster for anyone inactive, under-eating, or skipping resistance work. The most effective defense is loading bone on purpose. Strength training pulls on bone and signals it to densify, and it builds the balance and stability that prevent the falls that fracture weak bone in the first place. Plyometrics — jumping, hopping, the explosive movements most people skip — add the dynamic, high-impact load that bone responds to best, especially in the hips and lower body where osteoporotic fractures tend to happen. And these habits compound, so the work done in your twenties, thirties, and forties sets your fracture risk decades later.

Movement only pays off if the raw materials are there, and strong bone is a team effort. Calcium is the building mineral, but it needs vitamin D to be absorbed, magnesium to keep its balance, and vitamin K to direct it into bone rather than into blood vessels. Protein matters more than most people assume — bone isn't pure mineral, it's built on a protein matrix, largely collagen, that gives it flexibility and structure (and collagen isn't just for women). Chronic under-eating and crash dieting starve that whole system. Sitting on top of all of it are the hormones: estrogen slows bone breakdown in both sexes, which is why loss accelerates after menopause; testosterone supports bone-building; and chronically elevated cortisol — from stress, poor sleep, or long-term steroids — tips the balance toward loss.

That interconnection is what makes the GLP-1 question more complicated than the marketing suggests. The medications aren't villains — for the right person they're a genuine tool. But rapid weight loss strips muscle along with fat, and appetite suppression can drop protein and nutrient intake too low to maintain bone. Push the first domino — the number on the scale — and muscle, bone, and recovery fall behind it. Current research ties the bone concern more to that muscle loss and reduced loading than to any direct effect of the drug, and it points back to the same protections that build bone in the first place: enough protein, calcium, and vitamin D, plus resistance training. Which is the reassuring part — bones are more in your control than they feel. Ask for bone-density and hormone markers at the next blood draw, train with load and impact, eat enough protein, and start early, because this is a skeleton you build over decades, not weeks. No adamantium required.

KEY TAKEAWAYS

• Bones are living tissue, not a static frame. They constantly remodel — osteoclasts break down old bone, osteoblasts build new — and they respond to load just like muscle does.
• Use it or lose it. Peak bone mass arrives in your late twenties to early thirties; after that it declines, faster if you're inactive, under-eating, or skipping resistance training.
• Muscle and bone are directly linked. Building muscle pulls on bone and helps maintain density — so strength training does double duty.
• Plyometrics matter and get ignored. Jumping, hopping, and explosive movement load the hips and lower body where fractures happen. Start early; they get harder to begin later.
• Bone nutrition is a team. Calcium needs vitamin D to absorb, magnesium and vitamin K to be directed properly, and protein/collagen to maintain the bone's structural matrix. Collagen isn't just for women.
• Hormones set the balance. Estrogen (in both sexes), testosterone, and cortisol all influence whether you're building bone or losing it — which is why bone loss accelerates after menopause and with chronically high stress.
• GLP-1s deserve nuance. Useful for the right patient, but rapid weight loss can cost muscle and bone, especially if protein and training fall off. Current research links the concern to muscle loss and reduced loading more than to a direct drug effect — and resistance training plus adequate protein, calcium, and vitamin D are the recognized protections.
• It's a domino chain. People focus on the first domino (the number on the scale) and miss everything connected behind it. Looking skinnier isn't the same as getting healthier.

Links & Notes

• Submit your questions to the show!